| pubmed-article:11605085 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11605085 | lifeskim:mentions | umls-concept:C0028040 | lld:lifeskim |
| pubmed-article:11605085 | lifeskim:mentions | umls-concept:C0528200 | lld:lifeskim |
| pubmed-article:11605085 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11605085 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:11605085 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:11605085 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11605085 | pubmed:dateCreated | 2001-10-17 | lld:pubmed |
| pubmed-article:11605085 | pubmed:abstractText | Various compounds believed to selectively interact with the 5-HT(2C) receptor have been demonstrated to alter the functioning of ascending dopamine systems. We postulated that this functional interaction may extend to the behavioural effects of drugs of abuse whose rewarding properties are critically dependent upon mesolimbic DA activity. | lld:pubmed |
| pubmed-article:11605085 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11605085 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11605085 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11605085 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:11605085 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:11605085 | pubmed:author | pubmed-author:HigginsG AGA | lld:pubmed |
| pubmed-article:11605085 | pubmed:author | pubmed-author:CorrigallW... | lld:pubmed |
| pubmed-article:11605085 | pubmed:author | pubmed-author:GrottickA JAJ | lld:pubmed |
| pubmed-article:11605085 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11605085 | pubmed:volume | 157 | lld:pubmed |
| pubmed-article:11605085 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11605085 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11605085 | pubmed:pagination | 292-8 | lld:pubmed |
| pubmed-article:11605085 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:meshHeading | pubmed-meshheading:11605085... | lld:pubmed |
| pubmed-article:11605085 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11605085 | pubmed:articleTitle | Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine. | lld:pubmed |
| pubmed-article:11605085 | pubmed:affiliation | PRBN-B, F. Hoffmann-La Roche Ltd, Basel, Switzerland. | lld:pubmed |
| pubmed-article:11605085 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11605085 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11605085 | lld:pubmed |
